Xeris Biopharma grants director Taddese 22,365 restricted stock units
XERS•Xeris Biopharma granted director Menassie Taddese 22,365 common shares on November 2, 2026, and 31,499 stock options with a $10.17 exercise price that expire November 2, 2036.
1. Equity awards
Xeris Biopharma granted director Menassie Taddese 22,365 common shares and 31,499 stock options on November 2, 2026. The options have a $10.17 exercise price and expire November 2, 2036.
